Savolitinib combine with Durvalumab in EGFR wild-type locally advanced or metastatic NSCLC

Trial Identifier: D5083C00002
Sponsor: AstraZeneca
Start Date: November 2022
Primary Completion Date: August 2025
Study Completion Date: August 2025
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, 100021
CN Beijing, CN, 100039
CN Beijing, CN, CN-100730
CN Changsha, CN, 410011
CN Chongqing, CN, 400010
CN Hangzhou, CN, 310009
CN Hangzhou, CN, 310003
CN Jinan, CN, 250021
CN Kunming, CN, 650118
CN Nanchang, CN, 330006
CN Ningbo, CN, 315100
CN Shanghai, CN, 200030
CN Wenzhou, CN, 325000
CN Wuhan, CN, 430030
CN Wuhan, CN, 430022
CN Zhengzhou, CN, 450000